Celldex Therapeutics (NASDAQ:CLDX) had its target price increased by analysts at Cantor Fitzgerald from $12.00 to $18.00 in a research note issued on Wednesday, The Fly reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 44.81% from the stock’s current price. Cantor Fitzgerald also issued estimates for Celldex Therapeutics’ FY2020 earnings at ($1.76) EPS.
Several other analysts also recently issued reports on CLDX. HC Wainwright reiterated a “buy” rating and set a $16.00 price target (down previously from $19.00) on shares of Celldex Therapeutics in a research note on Friday, March 27th. Zacks Investment Research downgraded Celldex Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. BidaskClub raised Celldex Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Finally, ValuEngine cut Celldex Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Celldex Therapeutics has a consensus rating of “Hold” and a consensus price target of $12.33.
Shares of NASDAQ CLDX opened at $12.43 on Wednesday. The business’s 50-day moving average price is $5.82 and its two-hundred day moving average price is $3.14. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.12 and a quick ratio of 5.12. Celldex Therapeutics has a one year low of $1.50 and a one year high of $13.91. The company has a market capitalization of $301.79 million, a P/E ratio of -4.20 and a beta of 3.46.
Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.02). Celldex Therapeutics had a negative net margin of 948.81% and a negative return on equity of 47.60%. The firm had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $1.28 million. On average, equities analysts anticipate that Celldex Therapeutics will post -3.09 EPS for the current year.
In other news, CEO Anthony S. Marucci purchased 15,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was purchased at an average price of $2.99 per share, with a total value of $44,850.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Samuel Bates Martin purchased 9,750 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was purchased at an average cost of $2.99 per share, with a total value of $29,152.50. The disclosure for this purchase can be found here. Insiders have purchased a total of 41,170 shares of company stock valued at $126,778 in the last three months. 2.40% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC raised its holdings in Celldex Therapeutics by 20.4% in the 1st quarter. Acadian Asset Management LLC now owns 298,649 shares of the biopharmaceutical company’s stock valued at $496,000 after acquiring an additional 50,583 shares in the last quarter. TSP Capital Management Group LLC raised its holdings in Celldex Therapeutics by 14.9% in the 1st quarter. TSP Capital Management Group LLC now owns 410,017 shares of the biopharmaceutical company’s stock valued at $681,000 after acquiring an additional 53,127 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Celldex Therapeutics by 8.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,115,368 shares of the biopharmaceutical company’s stock valued at $2,487,000 after acquiring an additional 89,083 shares in the last quarter. 20.99% of the stock is owned by hedge funds and other institutional investors.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.
See Also: Fiduciary
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.